CN111039939B - 用作蛋白质聚集抑制剂的杂芳基酰胺 - Google Patents

用作蛋白质聚集抑制剂的杂芳基酰胺 Download PDF

Info

Publication number
CN111039939B
CN111039939B CN201911278647.XA CN201911278647A CN111039939B CN 111039939 B CN111039939 B CN 111039939B CN 201911278647 A CN201911278647 A CN 201911278647A CN 111039939 B CN111039939 B CN 111039939B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911278647.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111039939A (zh
Inventor
E·M·斯托金
W·赖斯德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Youshibi Biomedical Co ltd
Original Assignee
Youshibi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111039939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Youshibi Biomedical Co ltd filed Critical Youshibi Biomedical Co ltd
Priority to CN201911278647.XA priority Critical patent/CN111039939B/zh
Publication of CN111039939A publication Critical patent/CN111039939A/zh
Application granted granted Critical
Publication of CN111039939B publication Critical patent/CN111039939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201911278647.XA 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺 Active CN111039939B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911278647.XA CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US61/933,246 2014-01-29
US201462078895P 2014-11-12 2014-11-12
US62/078,895 2014-11-12
CN201580017216.1A CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
CN201911278647.XA CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580017216.1A Division CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Publications (2)

Publication Number Publication Date
CN111039939A CN111039939A (zh) 2020-04-21
CN111039939B true CN111039939B (zh) 2023-09-19

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911278647.XA Active CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
CN201580017216.1A Active CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580017216.1A Active CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Country Status (38)

Country Link
US (3) US9738635B2 (https=)
EP (2) EP3348556B1 (https=)
JP (2) JP6619741B2 (https=)
KR (1) KR102383038B1 (https=)
CN (2) CN111039939B (https=)
AP (1) AP2016009347A0 (https=)
AU (1) AU2015211119B2 (https=)
BR (2) BR112016017344B1 (https=)
CA (1) CA2937967C (https=)
CL (1) CL2016001918A1 (https=)
CR (1) CR20160394A (https=)
CY (2) CY1120348T1 (https=)
DK (2) DK3099684T3 (https=)
EA (1) EA032374B1 (https=)
EC (1) ECSP16070327A (https=)
ES (2) ES2808978T3 (https=)
HK (1) HK1231470A1 (https=)
HR (2) HRP20180813T1 (https=)
HU (2) HUE040274T2 (https=)
IL (1) IL246987B (https=)
LT (2) LT3099684T (https=)
ME (1) ME03800B (https=)
MX (1) MX2016009896A (https=)
MY (1) MY187450A (https=)
NZ (1) NZ722487A (https=)
PE (1) PE20161393A1 (https=)
PH (1) PH12016501493A1 (https=)
PL (2) PL3348556T3 (https=)
PT (2) PT3348556T (https=)
RS (2) RS60547B1 (https=)
SA (1) SA516371579B1 (https=)
SG (1) SG11201606108RA (https=)
SI (2) SI3348556T1 (https=)
SM (2) SMT201800318T1 (https=)
TR (1) TR201809440T4 (https=)
UA (1) UA118209C2 (https=)
WO (1) WO2015116663A1 (https=)
ZA (1) ZA201605246B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009347A0 (en) 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190112031A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체
CN110198938B (zh) 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
JP7283699B2 (ja) * 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
JP2020529432A (ja) * 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
AU2018360514A1 (en) * 2017-10-31 2020-05-14 Loma Linda University Methods for treating traumatic brain injury
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2023125376A1 (zh) 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
EP4611895A1 (en) * 2022-11-02 2025-09-10 AC Immune SA Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101124216A (zh) * 2004-12-21 2008-02-13 阿斯利康(瑞典)有限公司 杂环MCHr1拮抗剂及其在治疗中的用途
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
EP2155226A2 (en) * 2007-06-14 2010-02-24 The Regents of the University of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
DK1697371T3 (da) * 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
NZ553734A (en) * 2004-09-20 2011-01-28 4Sc Ag Novel thiazole derivatives as NF-kappaB inhibitors
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
SG172738A1 (en) * 2005-07-29 2011-07-28 4Sc Ag Novel heterocyclic nf-kb inhibitors
AU2007224659A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic NF-KB inhibitors
EP2491026A1 (en) * 2009-10-20 2012-08-29 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
MX2014011615A (es) 2012-03-28 2015-01-19 Neuropore Therapies Inc Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina.
CN104703604A (zh) 2012-07-16 2015-06-10 神经孔疗法股份有限公司 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物
AP2016009347A0 (en) 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN110198938B (zh) 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101124216A (zh) * 2004-12-21 2008-02-13 阿斯利康(瑞典)有限公司 杂环MCHr1拮抗剂及其在治疗中的用途
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2155226A2 (en) * 2007-06-14 2010-02-24 The Regents of the University of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗稳 ; 赵永梅 ; 田润果 ; 苏亚彬 ; 洪琛 ; .双烟碱衍生物作为胆碱酯酶和β-淀粉样蛋白双功能抑制剂的设计、合成及活性.药学学报.2013,(11),第47-52页. *

Also Published As

Publication number Publication date
SG11201606108RA (en) 2016-08-30
HRP20201107T8 (hr) 2020-12-11
AU2015211119A1 (en) 2016-08-11
JP2017505779A (ja) 2017-02-23
NZ722487A (en) 2022-04-29
HRP20201107T1 (hr) 2020-10-30
AU2015211119B2 (en) 2019-05-30
MX2016009896A (es) 2017-01-11
ME03800B (me) 2021-04-20
US20180093979A1 (en) 2018-04-05
ZA201605246B (en) 2022-05-25
PL3348556T3 (pl) 2020-11-02
US11078196B2 (en) 2021-08-03
PL3099684T3 (pl) 2018-09-28
EP3348556B1 (en) 2020-04-29
BR122018001892B1 (pt) 2023-05-02
SI3099684T1 (en) 2018-08-31
BR112016017344A2 (pt) 2017-10-03
HUE050964T2 (hu) 2021-01-28
US20160207912A1 (en) 2016-07-21
ES2675301T3 (es) 2018-07-10
PH12016501493B1 (en) 2017-02-06
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
DK3099684T3 (en) 2018-07-16
EP3099684B8 (en) 2018-07-04
HRP20180813T1 (hr) 2018-07-27
CY1120348T1 (el) 2019-07-10
KR20160113287A (ko) 2016-09-28
HUE040274T2 (hu) 2019-03-28
IL246987A0 (en) 2016-09-29
ES2808978T8 (es) 2021-03-22
PE20161393A1 (es) 2017-01-08
SMT202000376T1 (it) 2020-09-10
US20190308965A1 (en) 2019-10-10
SA516371579B1 (ar) 2019-07-16
HK1231470A1 (zh) 2017-12-22
JP6619741B2 (ja) 2019-12-11
CL2016001918A1 (es) 2017-01-13
RS57533B1 (sr) 2018-10-31
JP6783900B2 (ja) 2020-11-11
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
MY187450A (en) 2021-09-22
CN106132960B (zh) 2019-12-17
CA2937967A1 (en) 2015-08-06
EA201691529A1 (ru) 2017-01-30
AU2015211119A8 (en) 2016-12-15
SI3348556T1 (sl) 2020-10-30
DK3348556T3 (da) 2020-08-03
IL246987B (en) 2021-12-01
CN106132960A (zh) 2016-11-16
ES2808978T3 (es) 2021-03-02
PH12016501493A1 (en) 2017-02-06
EP3099684B1 (en) 2018-04-04
BR112016017344B1 (pt) 2023-05-16
LT3348556T (lt) 2020-08-10
RS60547B1 (sr) 2020-08-31
JP2019163321A (ja) 2019-09-26
EP3099684A1 (en) 2016-12-07
EA032374B1 (ru) 2019-05-31
CY1123374T1 (el) 2021-12-31
LT3099684T (lt) 2018-06-25
EP3348556A1 (en) 2018-07-18
PT3099684T (pt) 2018-10-22
SMT201800318T1 (it) 2018-07-17
WO2015116663A8 (en) 2016-09-15
PT3348556T (pt) 2020-07-27
CN111039939A (zh) 2020-04-21
CR20160394A (es) 2016-11-01
KR102383038B1 (ko) 2022-04-05
CA2937967C (en) 2022-07-26
TR201809440T4 (tr) 2018-07-23
ECSP16070327A (es) 2018-05-31
AP2016009347A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
CN111039939B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
JP7100043B2 (ja) タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体
JP2020505369A (ja) タンパク質凝集のモジュレーターとしての二環式ビス−ヘテロアリール誘導体
JP7100042B2 (ja) タンパク質凝集のモジュレーターとしてのアルコキシビス－ヘテロアリール誘導体
JP6159388B2 (ja) タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体
WO2019233745A1 (en) Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
HK40023286A (en) Heteroaryl amides as inhibitors of protein aggregation
HK1230613A1 (en) Heteroaryl amides as inhibitors of protein aggregation
HK1230613B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺
HK40023286B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023286

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant